Tech Company Financing Transactions
Janux Therapeutics Funding Round
Janux Therapeutics, operating out of La Jolla, scored $125 million from RA Capital, Avalon Ventures and Bregua.
Transaction Overview
Company Name
Announced On
4/21/2021
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds of the financing will help support the advancement of Janux's pipeline of next generation T cell engager immunotherapies, including a PSMA-TRACTr, EGFR-TRACTr, and TROP2-TRACTr, into initial proof of concept clinical trials.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11099 N. Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Janux Therapeutics is developing safe, effective novel immunotherapies with the company's proprietary TRACTr technology. Janux's TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Campbell
Chief Financial Officer
Tighe Reardon
Vice President
Charles Winter
VP - Bus. Development
Andrew Meyer
VP - R & D
Tommy Diraimondo
Browse more venture capital transactions:
Prev: 4/21/2021: Aloe Care Health venture capital transaction
Next: 4/21/2021: CI Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs